Quote:PRE5 will primarily enroll patients receiving first- or second-line treatment, while PRE7 will focus on patients receiving second-line treatment. Both studies will include patients with a CPS of less than 10.
"In KEYNOTE-355, approximately 38% of previously untreated locally recurrent inoperable or metastatic TNBC tumors had a combined positive score (CPS) of 10 or higher, and approximately 75% had CPS of 1 or higher, by the 22C3 assay.2
A CPS of 10 or higher is currently the only PD-L1 threshold that gates a breast cancer treatment decision in the United States. It governs both the first-line pembrolizumab plus chemotherapy indication and the June 2026 sacituzumab govitecan plus pembrolizumab indication."
Pembro + sacituzumab a first line treatment in only 38% of the population. This study, taking all comers, should get the attention of Merck...